

REMARKS/ARGUMENTS

In response to the Restriction Requirement mailed May 7, 2008, Applicants provisionally elected Group I, Claims 1-16 and 50-58, drawn to a method of selecting a patient, and as species, the HLA tetramer technique and the SEQ ID No.: 2 peptide, with traverse on the grounds that no adequate reasons and/or examples had been provided to support a conclusion of patentable distinctiveness between the identified groups.

It was thought that the election of the Group I claims satisfied the requirement to identify readable claims. The Applicants have been contacted by mail and they confirm that Claims 1-16 and 50-58 read on the elected species.


Applicants respectfully submit that the above-identified application is now in condition for examination on the merits, and early notice of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413 -2220
(OSMMN 06/04)


James H. Knobel
Registration No. 22,630